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Disease relapse remains a major obstacle to the success of allogeneic hematopoietic stem cell transplantation
(HSCT), yet little is known about the relevant prognostic factors after relapse. We studied 1080 patients
transplanted between 2004 and 2008, among whom 351 relapsed. The 3-year postrelapse overall survival
(prOS) rate was 19%. Risk factors for mortality after relapse included shorter time to relapse, higher disease
risk index at HSCT, myeloablative conditioning, high pretransplantation comorbidity index, and graft-versus-
host disease (GVHD) occurring before relapse. Important prognostic factors did not vary by disease type.
Based on this, we could stratify patients into 3 groups, with 3-year prOS rates of 36%, 14%, and 3% (P < .0001).
This score was validated in an historical cohort of 276 patients. Postrelapse donor lymphocyte infusion or
repeat HSCT was associated with improved prOS, as was the development of GVHD after relapse. These
differences remained signiﬁcant in models that accounted for other prognostic factors and in landmark
analyses of patients who survived at least 2 months from relapse. The results of this study may aid with
prognostication and management of patients who relapse after HSCT and motivate the design of clinical trials
aimed at relapse prevention or treatment in higher-risk patients.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION prognostic factors after relapse, (2) determining whether
Advances in allogeneic hematopoietic stem cell trans-
plantation (HSCT) have improved the safety of the proce-
dure and signiﬁcantly broadened its applicability. Despite
this, disease relapse still represents a major barrier to
success for patients transplanted for hematologic malig-
nancies. In fact, relapse is the principal cause of treatment
failure for patients undergoing reduced-intensity condi-
tioning (RIC) or nonmyeloablative HSCT. Much work has
focused on identifying factors at the time of HSCT that
increase the risk for relapse and on devising strategies for its
prevention and management [1-8], but little is known about
the determinants of outcome after relapse. Recent studies,
notably from the European Group for Blood and Marrow
Transplantation, describe the outcomes in subgroups of
relapsing patients, especially patients with acute leukemia
receiving RIC HSCT [9-11], but no study has yet identiﬁed the
factors that inﬂuence survival after relapse in broader
cohorts of patients across multiple disease and trans-
plantation types. This information is necessary both to
assess the prognosis of patients who relapse after HSCT and
to optimally select patients for clinical trials of postrelapse
treatment strategies.
We therefore undertook an observational study of 1080
consecutive adult patients with hematologic malignancies
who underwent HSCT at Dana-Farber Cancer Institute/
Brigham and Women’s Hospital between 2004 and 2008,
with the following goals: (1) elucidating the importantedgments on page 1718.
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13.09.011those factors are disease-speciﬁc or whether the disease
risk itself is an independent prognostic factor, and (3) de-
scribing the outcome of various postrelapse intervention
strategies. Three-hundred ﬁfty-one patients (33%) relapsed
and form the basis of this report. We determined prognostic
factors for postrelapse overall survival (prOS), devised
a simple risk score to stratify patients into different risk
groups for prOS, validated this score in an historical control
population, and examined the impact of postrelapse strat-
egies on outcome.METHODS
Patients
We analyzed consecutive adult patients who underwent their ﬁrst HSCT
with myeloablative conditioning (MAC) or RIC at Dana-Farber Cancer
Institute/Brigham and Women’s Hospital within the 4-year period from
2004 to 2008. Patients receiving transplantation for benign hematologic
conditions were excluded. Individual medical records of all relapsed
patients (deﬁned as progression or relapse of disease any time after HSCT)
were examined. Molecular or cytogenetic relapses were not considered as
relapse events.
We collected data on comorbidities necessary to calculate the Hema-
topoietic Cell Transplantation-Comorbidity Index (HCT-CI) [12], when
available. Comorbidity information was extracted retrospectively for
patients who underwent HSCT between 2005 and 2007 and prospectively
collected for patients who underwent HSCT after 2007. Disease Risk Index
(DRI) was assigned as previously described [13], using the latest available
tumor cytogenetics information for patients with acute myeloid leukemia
(AML) or myelodysplastic syndrome (MDS). The DRI accounts for disease
risk, including cytogenetics risk for AML and MDS, and for disease status at
the time of transplantation, in general separating patients in complete or
partial remission from those with active disease.
To validate the postrelapse risk score, we used an historical control cohort
of 869 patientswho received their ﬁrst HSCT between 1998 and 2003, among
whom 32% relapsed. Institutional review board approval was obtained from
the Ofﬁce for Human Research Studies of the Dana-Farber/Harvard Cancer
Center to conduct this study.Transplantation.
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Patients were transplanted on a variety of treatment plans and investi-
gational protocols. MAC regimens consisted mostly of cyclophosphamide
(3600 mg/m2 or 120 mg/kg) plus total body irradiation (1400 cGy in 7 frac-
tions) or busulfan (12.8 mg/kg intravenously) plus cyclophosphamide
(3600mg/m2). RIC regimens consisted principally of ﬂudarabine (120mg/m2)
plus intravenous low-dose busulfan (3.2 to 6.4mg/kg). Patients received bone
marrow or peripheral blood stem cells from HLA-matched or mismatched,
related or unrelated donors, or double umbilical cord blood units. Graft-
versus-host disease (GVHD) prophylaxis consisted mostly of tacrolimus
combined with methotrexate, with or without sirolimus.
Supportive care for all patients followed institutional standards. The
practice at our center is to attempt immunosuppression withdrawal in all
patients at relapse, except for patients whose condition makes it unlikely
they would survive for more than a fewweeks or for whom the severity and
activity of GVHD contraindicates immunosuppression withdrawal.
Donor lymphocyte infusion (DLI) is generally attempted when patients
are immunosuppression-free without signiﬁcant GVHD, with more than
about 20% donor chimerism, and when DLI can be obtained from the donor.
In cases where no DLI can be obtained or donor chimerism is too low,
patients are considered for repeat HSCT. This practice did not change over
the course of the study.
Statistical Analysis
Patient baseline characteristics were reported descriptively. prOS was
deﬁned as the time from documentation of relapse or progression to death
from any cause and calculated using the Kaplan-Meier method. Patients
whowere alive or lost to follow-upwere censored at the time last seen alive.
The log-rank test was used for comparisons of Kaplan-Meier curves.
Potential prognostic factors for OS were examined in the proportional
hazards model; in the multivariable models, variables were added by
stepwise selection (see Table 2 for variables considered).
The proportional hazards assumption for each variable of interest was
tested and interaction terms examined. The linearity assumption for
continuous variables was examined using restricted cubic spline estimates
of the relationship between the continuous variable and log relative hazard,
and the cut-off points of these variables were based on the change of the log
relative hazards.
All P values are 2-sided with a signiﬁcance level of .05. The c-statistic
[14] was used to compare model ﬁt using the Hmisc package in R (the CRAN
project, R Foundation for Statistical Computing, Vienna, Austria). To build
a risk score, points were assigned roughly following the hazard ratio for
prOS in the multivariable model. The only exception was for high/very high
DRI, which was assigned an integral number of points to keep the score
simple. All calculations were done using SAS 9.3 (SAS Institute, Cary, NC) and
R version 2.13.2 (the CRAN project, R Foundation for Statistical Computing,
Vienna, Austria).
RESULTS
Patients
Among the 1080 studied patients, 351 (33%) relapsed at
amedian time of 4.5months (range, 0 to 59) after HSCT. Their
characteristics are listed in Table 1. The median age was
52 years (range,19 to71).Most had intermediate- or high-risk
disease by DRI. Two thirds had received a RIC HSCT. Seventy-
two percent were on immunosuppression at the time of
relapse (51% for GVHD prophylaxis and 21% for GVHD treat-
ment). In all, 35% had had GVHD before the time of relapse.
Prognostic Factors for Postrelapse Survival
Table 2 shows the results of univariable and multivariable
analyses for prOS among the 351 relapsed patients. In uni-
variable analyses, variables associated with inferior prOS
were higher DRI, shorter time to relapse (TTR), MAC, and
HCT-CI of 3 or above. The 3-year prOS rate for patients who
underwent MAC was 10%, compared with 23% for those who
received an RIC HSCT (P ¼ .002). In addition, being on
immunosuppression at the time of relapse was associated
with worse prOS. Because TTR was the most important
prognostic factor, we examined its association with other
important baseline variables. A shorter TTR was associated
with higher DRI, older age, and RIC. We compared the
prognostic value of the DRI with that of 2 other possibleclassiﬁcation schemes: myeloid versus lymphoid and the
low-risk/high-risk system used in a recent Blood and
Marrow Transplant Clinical Trials Network trial [15]. The c-
statistic was highest for the DRI, which we therefore retained
as the risk stratiﬁcation scheme for further analyses.
In multivariable analyses, the same factors remained
signiﬁcant except for being on immunosuppression at the
time of relapse (hazard ratio [HR] for mortality ¼ .8, P ¼ .4);
instead, the occurrence of GVHD (acute or chronic) before
relapse was associated with signiﬁcantly inferior prOS in the
multivariable models. This discrepancy can be explained by
the strong association between being on immunosuppres-
sion, history of GVHD, and time of relapse, the latter of which
remained very strongly associated with prOS in the multi-
variable models. Patients who relapsed earlier were more
likely to be on immunosuppression at the time of relapse
(95% of patients who relapsed within 3 months were still on
immunosuppression, compared with 87% of those who
relapsed within 3 to 6 months, 47% of those who relapsed
within 6 to 24 months and 18% of those who relapsed after
2 years, P < .0001). Conversely, patients who relapsed earlier
were less likely to have had prior or active GVHD at the time
of relapse (15% among those with TTR < 3 months, 27% for 3
to 6 months, 53% for 6 to 24 months, and 77% for
>24 months, P < .0001), which likely explains why GVHD
was not signiﬁcant in the univariable models, even when
only grades III or IV acute GVHD was considered. GVHD was
an adverse factor for prOS in the multivariable models
regardless of the type of GVHD (acute versus chronic) or
whether the GVHD was active or not at the time of relapse.
There were no relevant signiﬁcant interactions between
prognostic variables in the multivariable models.
We obtained similar results in multivariable models built
separately for MAC and RIC patients, although the impact of
the DRI was less pronounced among patients who received
MAC. Because RIC was associated with shorter TTR in this
cohort, which could inﬂate the apparent beneﬁt of RIC in the
prOS multivariable model, we also checked models that did
not include TTR; RIC remained signiﬁcantly associated with
superior prOS even in those models (HR for mortality asso-
ciated with RIC ¼ .7; P ¼ .022).
Prognostic Score for prOS
We constructed a simple score using the signiﬁcant
factors established previously (Table 3). Because the HR
associated with a high HCT-CI was only 1.4 and because the
addition of the HCT-CI to the model did not noticeably
improve model ﬁt (c-statistic of model with HCT-CI .680
versus .675 for a model without HCT-CI), it was not included
in the score. The score can be calculated by summing the
points for a given patient among TTR (1 point for 6 to
24 months, 2 for 3 to 6 months, 3 for <3 months), DRI (1
point for intermediate, 2 for high/very high index), condi-
tioning intensity (1 point for myeloablative), and prior GVHD
(1 point). This score stratiﬁed the cohort into 3 groups with
very different prOS rates (Figure 1A and Table 3). Patients
with 0 to 3 points had a 3-year prOS rate of 36%, patients
with 4 points a 3-year prOS rate of 14%, and patients with 4 to
7 points a 3-year prOS rate of 3%. Among the low-risk group,
46 patients (13% of the total population) had fewer than 3
risk factors and a 3-year prOS rate of 51%. Because this is
a surprisingly high survival rate, we examined the charac-
teristics of this group: 65% were 50 years or older; only 4%
had relapsed within 6 months of HSCT, whereas 67% had
relapsed within 6 to 24 months of transplant and 28% had
Table 1
Baseline Patient Characteristics
Variable N (%)*
Number of patients 351
Age, y, median (range) 52 (19-71)
Gender
Male 192 (55)
Female 159 (45)
Disease
ALL 31 (9)
AMLy 145 (41)
Favorable cytogenetics 3 (1)
Intermediate cytogenetics 97 (28)
Adverse cytogenetics 33 (9)
Cytogenetics not available 12 (3)
CLL 20 (6)
CML 8 (2)
Hodgkin lymphoma 28 (8)
MDSz 43 (12)
Intermediate cytogenetics 22 (6)
Adverse cytogenetics 17 (5)
Cytogenetics not available 4 (1)
Multiple myeloma 24 (7)
Myeloproliferative neoplasms 11 (3)
Non-Hodgkin lymphoma 41 (12)
Stage at HSCT
CRx 134 (38)
PR 75 (21)
Induction failure 49 (14)
Active relapsex 55 (16)
Untreated 38 (11)
DRIk
Low 24 (7)
Intermediate 188 (54)
High 126 (36)
Very high 13 (4)
HCT-CI{
0 78 (35)
1-2 73 (33)
3þ 70 (32)
HSCT performed on protocol
Yes 122 (35)
No 229 (65)
Donor match
MRD 152 (43)
Non-MRD 199 (57)
MUD 145 (41)
MM 54 (15)
Mismatched URD 51 (15)
Mismatched relative 3 (1)
Graft source
PB# 306 (87)
BM 16 (5)
UCB 29 (8)
Conditioning
MAC 117 (33)
RIC 234 (67)
GVHD prophylaxis
CnI þ Mtx 84 (24)
CnI þ Siro þ/ Mtx 236 (67)
TCD/other 31 (9)
CMV serostatus**
Recipient or donor þ 223 (64)
Gender matchingyy
Female to male 81 (23)
Male to female 77 (22)
Female to female 81 (23)
Male to male 11 (32)
Year of HSCT, median (range) 2006 (2004-2008)
Months from HSCT to relapse, median (range) 4 (0-59)
0-3 118 (34)
3-6 93 (27)
6-24 118 (34)
>24 22 (6)
Prerelapse immune status
On immunosuppression at relapse 252 (72)
(continued)
Table 1
(continued)
Variable N (%)*
For GVHD prophylaxis 179 (51)
For GVHD treatment 73 (21)
Any prior GVHD 123 (35)
Prior acute GVHD 76 (22)
Prior chronic GVHD 60 (17)
Postrelapse treatment
Chemotherapy/radiotherapy 193 (55)
Any immune manipulation 259 (74)
Immunosuppression withdrawal 216 (62)
DLI 88 (25)
Repeat HSCT 32 (9)
Months of follow-up for survivors after relapse,
median (range)
39 (5-90)
ALL indicates acute lymphoblastic leukemia; CLL, chronic lymphocytic
leukemia; CML, chronic myelogenous leukemia; CR, complete remission;
PR, partial remission; MRD, matched related donor; MUD, matched unre-
lated donor; MM, mismatched donor; PB, peripheral blood; BM, bone
marrow; UCB, umbilical cord blood; CnI, calcineurin inhibitor; Mtx, meth-
otrexate; Siro, sirolimus; TCD, T cell depletion; CMV, cytomegalovirus.
* Percentages may not add to 100 because of rounding.
y Classiﬁed according to Armand et al. [18]
z Classiﬁed according to Armand et al. [19]
x CR includes CML in chronic phase; Active relapse includes CML in
advanced or blast phase.
k Classiﬁed according to Armand et al. [13]
{ Classiﬁed according to Sorror et al. [12]; data available on 221 patients;
percentages are given relative to patients with available data only.
# Including patients who received combined BM and PB.
** Data missing on 11 patients.
yy Data missing on 4 patients.
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65% had intermediate DRI, and none had high or very high
DRI; 89% had received a RIC transplant; 48% had acute
lymphoblastic leukemia, AML, or MDS; and 50% were
transplanted in complete remission.
To validate this score, we considered a cohort of 869
patients transplanted between 1998 and 2003, among whom
276 had relapsed. The 3-year prOS rate in this control cohort
was19%, as itwas in the training cohort (P¼ .9). ThemedianTTR
was 5.6 months, and the median agewas 46. Fewer patients in
the historical control had high/very high risk disease by DRI
(33% versus 40%), fewer underwent RICHSCT (37%versus 67%),
and fewer relapsed without prior GVHD (42% versus 65%),
compared with themain study cohort. Nonetheless, the prOS
rates among the 3 risk groups in the historical cohort were
very similar to that of the training cohort (Figure 1B).
Disease-Speciﬁc Risk Factors
The foregoing models were all built in a cohort of patients
that is heterogeneous with respect to disease, which was
accounted for through the use of a general risk index (the
DRI). However, it is possible that postrelapse risk factors
depend on the speciﬁc disease type. We therefore also built
multivariable models on speciﬁc subgroups, including
patients with myeloid diseases (AML, MDS, myeloprolifera-
tive diseases, or chronic myelogenous leukemia) and patients
with lymphoid diseases (acute lymphoblastic leukemia,
Hodgkin and non-Hodgkin lymphoma, and multiple
myeloma). We also built a model only for patients with AML
and 1 for all non-AML patients, because AML was the domi-
nant group in our cohort. For those analyseswe combined the
training and testing sets, with a total of 627 relapsed patients;
we therefore omitted HCT-CI from the models, because the
testing set patients did not have these data available. In all 4
models, the same factors remained signiﬁcant (ie, TTR,
Table 3
Outcomes by Risk Group
Number of Risk
Factors*
No. of Patients among
351 Patientsy
3-Yr OS
P < .0001z
(%)
HR for
Mortality
0-3 136 (39) 36 (27-44) Ref
4 98 (28) 14 (8-22) 2.0 (P < .0001)
5-7 117 (33) 3 (1-8) 4.3 (P < .0001)
* Risk factors are DRI (0 points for low, 1 point for intermediate, 2 points
for high or very high), TTR (0 points for >24 months, 1 point for
6-24 months, 2 points for 3-6 months, 3 points for <3 months), MAC
(1 point), and prior GVHD (1 point).
y Values in parentheses are percents.
z Values in parentheses are 95% conﬁdence intervals.
Table 2
Univariable and Multivariable Analyses for Overall Survival
Variable Univariable Multivariable*
HR P HR P
DRI
Low Ref Ref
Intermediate 1.8 .044 2.1 .062
High/very high 3.0 .0002 2.6 .017
TTR
0-3 mo 2.6 <.0001 3.7 <.0001
3-6 mo 1.6 .004 1.8 .003
6-24 mo Ref Ref
24 mo .7 .2 .4 .043
Conditioning
Myeloablative Ref Ref
Reduced intensity .7 .002 .6 .0001
HCT-CI*
0-2 points Ref Ref
3 þ points 1.8 .0001 1.4 .024
Prior GVHD
Noy Ref Ref
Yes 1.1 .4 1.9 .0005
On immunosuppression
at relapse
No Ref
Yes 1.8 <.0001
Age
<50 Ref
50 1.2 .2
Male .9 .5
Gender mismatching 1.0 .9
CMV seropositive donor
or recipient
1.0 .8
Donor type
MRD Ref
MUD 1.1 .5
Mismatched 1.1 .8
Graft source
PB Ref
BM 1.2 .5
UCB .8 .3
HSCT on protocol
No Ref
Yes .8 .2
GVHD prophylaxis
CnI þ Mtx Ref
CnI þ Siro þ/ Mtx .9 .2
TCD/Other .8 .3
Year of HSCT
2004-2005 Ref
2006-2008 1.0 .8
MRD indicates matched related donor; MUD, matched unrelated donor; PB,
peripheral blood; BM, bone marrow; UCB, umbilical cord blood; CnI, calci-
neurin inhibitor; Mtx, methotrexate; Siro, sirolimus; TCD, T cell depletion;
CMV, cytomegalovirus.
* Model built for only the 221 patients with available data. The same
variables were selected if HCT-CI was not included and all 351 patients were
included (not shown).
y Including patients with a history of GVHD without any active disease
and off systemic immunosuppression at the time of relapse.
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was that advanced age (50) was also an adverse risk factor
in the group of patients with myeloid disease and in the
entire non-AML cohort. The difference in model ﬁt for non-
AML patients with or without age was small. The difference
in the Akaike information criterion (a measure of multivari-
able model ﬁt) from inclusion of age in the model was 4,
comparedwith 17 for conditioning intensity,18 for DRI, 23 for
prior GVHD, and 86 for TTR. We therefore did not incorporate
age in the score and, more importantly conﬁrmed that
a nondisease-speciﬁc scoring system that incorporates
a general disease risk term is appropriate for estimating the
prognosis of relapsed patients.Postrelapse Treatment
We examined the outcomes of the 351 relapsed patients
based on the treatment received. Fifty-ﬁve percent received
cytotoxic therapy after relapse (chemotherapy or radio-
therapy); 74% received immune manipulation in the form of
immunosuppression withdrawal (62%), DLI (25%), or repeat
HSCT (9%). Withdrawal of immunosuppression at the time of
relapse did not appear to confer a beneﬁt in univariable or
multivariable models. In contrast, receipt of DLI was associ-
ated with signiﬁcantly better prOS rate (HR ¼ .4; P < .0001),
as was receipt of a second HSCT (HR ¼ .4; P ¼ .0003). The
3-year prOS rate appeared to be superior in patients who
received DLI or repeat HSCT compared with those who did
not (31% versus 13%; P < .0001); the outcomes after admin-
istration of DLI were similar to those after repeat HSCT
(Figure 2). Patients who received cytotoxic therapy after
relapse also appeared to have a better prOS rate (P ¼ .0005);
however, the beneﬁt was only apparent early (1-year prOS
rate was 39% versus 24%, whereas 3-year prOS rate was 19%
versus 18%) and was not apparent in multivariable models,
possibly because receipt of cytotoxic therapy was associated
with a longer TTR. In exploratory analyses, the apparent
beneﬁt of DLI or repeat HSCT extended across disease groups
except for chronic myelogenous leukemia and acute
lymphoblastic leukemia, but fewer than 10 patients with
each of those diseases received DLI/HSCT.
Naturally, there is a selectionbias associatedwith theuseof
post-relapse therapies. Indeed, patients with shorter TTR or
with higher HCT-CI were less likely to receive DLI/HSCT
(P¼ .002 and P¼ .0008, respectively). Despite this, the beneﬁt
of DLI/HSCT persisted in multivariable models in which all
prognostic factors were added (HR for mortality associated
with DLI/HSCT ¼ .4; P < .0001; in this model all other factors
remained signiﬁcant). Interestingly, the beneﬁt of DLI/HSCT
was evidentwhether or not patients had a history of GVHDby
the time of relapse. In contrast, receipt of cytotoxic therapy
was not associated with a signiﬁcant beneﬁt when DLI/HSCT
and the other risk factors in the relapse scorewere included in
the model (HR ¼ .8; P ¼ .10). Because patients who die early
after relapse are less likely to receive DLI/HSCT, we conducted
a landmark analysis considering only patients whowere alive
2months after relapse. In this group, both theprognostic score
and DLI/HSCT remained associated with improved survival in
a multivariable model (HR of DLI/HSCT ¼ .6; P ¼ .001).
We also examined the association between GVHD that
occurred after relapse and prOS. Among the 351 relapsed
patients, 85 (24%) developed acute or chronic GVHD after
relapse. Twenty-one of these patients (25%) had received
DLI/HSCT. We built multivariable models for prOS that
included TTR, DRI, conditioning intensity, prerelapse GVHD,
and receipt of DLI/HSCT, with the addition of postrelapse
Figure 1. prOS stratiﬁed by risk score. (A) prOS in the main cohort of 351 patients. (B) prOS in a historical cohort of 276 patients.
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were signiﬁcant: the HR for mortality of DLI/HSCT (compared
with neither) was .4 (P< .0001) and for postrelapse GVHD (as
a time-dependent variable) was .5 (P < .0001). In those
models, there was no apparent beneﬁt for patients who
received DLI/HSCT compared with those who developed
GVHD but never received DLI/HSCT (HR ¼ .7, P ¼ .08). These
ﬁndings were unchanged in landmark analyses of patients
who survived at least 2 months past relapse.Figure 2. prOS survival stratiﬁed by postrelapse treatment.DISCUSSION
It is generally accepted that the prognosis for patients
who relapse after HSCT is very poor. Nonetheless, by
analyzing a large cohort of patients with different diseases
and transplant types, we were able to distinguish important
prognostic factors in this population. The size of our obser-
vational cohort allowed us to untangle some of the con-
founding issues in this setting, such as time-to-relapse
confounding the association between immunosuppression
at the time of relapse and prOS, as well as to adjust for the
well-recognized difference in postrelapse outcome between
different diseases. In this respect it is notable that the major
prognostic factors for postrelapse survival do not appear to
depend on the disease type and that a generalized DRI seems
adequate to capture disease-speciﬁc features. Because of the
retrospective nature of this study, we could not analyze
whether the presence of minimal residual disease, which is
becoming increasingly recognized as an important prog-
nostic factor across many hematologic malignancies, signif-
icantly affects prerelapse or postrelapse outcomes.
TTR was a very strong prognostic factor in our cohort,
which is a recurrent ﬁnding inmost stem cell transplantation
outcome studies. TTR and disease risk likely both capture the
aggressiveness of the tumor and its relative susceptibility to
the graft-versus-tumor (GVT) effect. Similarly, because MAC
is usually associated with lower disease relapse compared
with RIC transplantation [16,17], patients who relapse after
MAC may have more aggressive or immunorefractory
disease, which could explain their worse prognosis in our
study. In our analyses, the worse prognosis of patients
relapsing after MAC HSCT was not solely due to the longer
time-to-relapse in those patients. The HCT-CI was also
weakly prognostic in our study, which may reﬂect the abilityof patients to tolerate further therapy. It is possible that HCT-
CI calculated at the time of relapse would be a better prog-
nostic marker than HCT-CI at the time of HSCT, but these data
were not available in our cohort.
The negative effect of prior GVHD on prOS is noteworthy.
It appeared to be independent of the type of GVHD or its
status (remitted or active) at the time of relapse; however, it
is possible that with a larger cohort differences between
those subsets or differences between patients with different
diseases (with different GVT susceptibility) might emerge.
The association between prior GVHD and prOS could be
explained by the fact that patients who relapse after having
experienced GVHD may have disease that is less sensitive to
the GVTeffect than patients who relapse without ever having
developed GVHD, in whom the GVT effect may not yet have
been tested. It is important to note that the adverse prog-
nosis of prior GVHD on prOS does not contradict the obser-
vation that GVHD may be protective after HSCT. Rather, it
implies that patients who still relapse after developing GVHD
fareworse than thosewho relapsewithout having developed
GVHD. This is also consistent with the apparent beneﬁcial
effect of postrelapse GVHD, regardless of whether or not this
is brought about by DLI/HSCT.
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pression taper, DLI, or HSCT are likely those who have had no
or minimal active GVHD at the time of relapse and in whom
a GVL effectmay yet be obtainedwith immunemanipulation.
It is also notable that immune manipulation (DLI/HSCT) was
associated with a clear prOS beneﬁt even in patients with
prior GVHD; therefore, although a history of prior GVHDmay
portend a worse outcome, it does not necessarily contrain-
dicate the use of immunotherapy. Here again, the selection
bias inherent in the use of DLI/HSCT must be acknowledged,
making it unlikely that those therapies were used in patients
with severe active GVHD at the time of relapse. Even though
no single prognostic variable eliminated the beneﬁt of DLI/
HSCT, their combination did, in that patients with a high risk
score (6 to 7 points) had a 3-year prOS rate of 0% with or
without DLI/HSCT. Naturally, the quantitative difference in
prOS provided by different postrelapse therapies may well
differ between diseases, and our study was not designed or
powered to detect those differences.
Although we did not ﬁnd a prognostic relevance to being
on immunosuppression at the time of relapse in multivari-
able model, this issue is quite complex. This variable is
inextricably related to the time of relapse, which appears in
our study to be the dominant driver of outcome. Aside from
that, patients who relapse on immunosuppression without
prior GVHD could be expected to do better because theymay
not yet have been exposed to a full-blown GVL effect,
whereas patients who relapse on immunosuppression with
prior GVHD may be expected to do worse given that they
have relapsed after evidence of immunologic graft activity.
Similarly, although we did not ﬁnd a beneﬁt to immune
withdrawal per se, the appearance of GVHD after immune
withdrawal without additional immunotherapy was associ-
ated with a survival advantage in time-dependent multi-
variable models, suggesting that immune withdrawal alone,
if it is associated with new-onset GVHD, may have a beneﬁ-
cial impact similar to that of DLI/HSCT.
Even though the relapse prognostic score proposed here
showedgood stratiﬁcation ability in an independent cohort of
patients transplanted earlier than those in the present cohort,
our study is still based on a single institution’s experience,
and it would be useful to validate this in other centers. In the
meantime, we hope that the results of this study help clini-
cians to assess the prognosis of patients who relapse after
HSCT, to target higher-risk patients for investigational inter-
ventions for relapse treatment or prevention, and perhaps
(again with the caveat of the unavoidable selection bias) to
inform the use of immunotherapy in this setting.ACKNOWLEDGMENTS
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